Sglt2 Inhibitors [invokana (canagliflozin), Forxiga (dapagliflozin), Xigduo (dapagliflozin/metformin), Jardiance (empagliflozin)] - Risk Of Diabetic Ketoacidosis

Recall Summary Health Canada is recalling four SGLT2 inhibitor diabetes medications (Invokana, Forxiga, Xigduo, and Jardiance) due to a risk of diabetic ketoacidosis, a serious condition where acid builds up in the blood. These medications are distributed across Canada. People taking these drugs should consult their healthcare provider about this safety concern.

Reason

Product safety

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2016-05-16

Status

Closed

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/00eee4ad-faa5-4126-89bc-7bd75516c97b